Pharma industry highly concerns about conflicts between medical and pharmaceutical associations over ‘Valsartan’
The pharmaceutical industry has shown high interests in recruiting the chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA).
In the circumstance where the antihypertensive ‘Valsartan’ case might extensively spread negative impacts, the industry has started to thin...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.